Next-Generation Multiple Myeloma Therapies Market to Reach USD 37.07 Billion by 2033, Driven by Accelerated Immunotherapy Approvals and Precision Medicine Advances - DataM Intelligence
Comunicato Precedente
Comunicato Successivo
Download PDF Brochure: https://www.datamintelligence.com/download-sample/next-generation-multiple-myeloma-therapies-market
Browse in-depth TOC on "Next-Generation Multiple Myeloma Therapies Market"
73 – Tables
67 – Figures
199 – Pages
Beyond therapeutics, diagnostics are experiencing a paradigm shift. A multicenter trial using whole-body MRI (MY-RADS) revealed that patients achieving imaging-negative status post-transplant had progression-free survival of 42 months versus 24 months in those with residual disease. In addition, a novel liquid biopsy platform, SWIFT-seq, detected circulating tumor cells in 90% of study participants, paving the way for non-invasive monitoring and potentially reducing reliance on traditional bone marrow biopsies.
The next-generation therapies market spans multiple drug classes, each contributing uniquely to improved outcomes and durable responses. Monoclonal Antibodies such as Darzalex, Darzalex Faspro, Sarclisa, and Empliciti continue to dominate frontline and maintenance regimens. Immunomodulators (IMiDs) including Revlimid and Pomalyst remain foundational agents, while emerging CELMoDs such as iberdomide and mezigdomide promise deeper immune modulation. Proteasome Inhibitors like Velcade, Kyprolis, and Ninlaro sustain relevance in multi-line therapy settings, supported by recent formulation advancements. Bispecific Antibodies such as Elrexfio (elranatamab), Tecvayli (teclistamab), Talvey (talquetamab), and Lynozyfic (linvoseltamab) are driving the next wave of targeted immune engagement. CAR T-Cell Therapies, including Abecma and Carvykti, continue to deliver unprecedented remission rates for patients with heavily pretreated disease, while Antibody-Drug Conjugates (ADCs) like Blenrep have re-entered the U.S. market in 2024 following updated trial results demonstrating improved benefit–risk profiles.
Recent Industry Developments
In August 2024, Takeda Pharmaceuticals launched NINLARO 0.5 mg capsules (ixazomib citrate) in Japan, expanding dosage flexibility for maintenance therapy in multiple myeloma. In August 2023, Janssen Biotech received FDA accelerated approval for TALVEY (talquetamab-tgvs), a first-in-class bispecific antibody targeting GPRC5D for RRMM patients after four or more prior lines of therapy. These milestones emphasize the global momentum toward precision-engineered, immune-based therapies that extend survival while minimizing treatment toxicity.
Market Outlook and Opportunities
The next decade promises significant transformation in the MM treatment paradigm.
Analyst Insight: "The evolving myeloma landscape in 2025 signals a shift from generalized therapy toward precision-driven, adaptive care," said DataM Intelligence's oncology research lead. "Bispecific antibodies and CAR-T therapies are redefining treatment expectations, while novel imaging and liquid biopsy tools like SWIFT-seq are making disease monitoring less invasive and more informative."
Request for Customized Sample Report as per Your Business Requirement: https://www.datamintelligence.com/customize/next-generation-multiple-myeloma-therapies-market
Market Segmentation Analysis
By Drug Class
The next-generation multiple myeloma market is segmented into Monoclonal Antibodies, Immunomodulators, Proteasome Inhibitors, Bispecific Antibodies, CAR T-Cell Therapies, Antibody-Drug Conjugates (ADCs), and Others.
By Route of Administration
By Distribution Channel
Regional Insights
United States
The United States remains the largest market for next-generation multiple myeloma therapeutics, accounting for over 45% of global revenue (USD 10.4 billion in 2024).
Japan
Japan's multiple myeloma market reached USD 1.2 billion in 2024 and is projected to hit USD 2.1 billion by 2033, growing at 6.1% CAGR.
Key Market Players: Major companies shaping the next-generation multiple myeloma market include Takeda Pharmaceuticals, Amgen Inc., Bristol-Myers Squibb Company, Johnson & Johnson (Janssen), Sanofi, GSK plc, Karyopharm Therapeutics, Novartis AG, Regeneron Pharmaceuticals, and Legend Biotech.
Highlights:
Collectively, the top five companies hold over 75% global market share, supported by deep oncology pipelines, patient-access initiatives, and strategic co-development alliances.
Buy This Report with Year-End Offer (Buy 1 report: Get 30% OFF | Buy 2 reports: Get 50% OFF each! Limited time offer): https://www.datamintelligence.com/buy-now-page?report=next-generation-multiple-myeloma-therapies-market
Related Report:
About DataM Intelligence:
DataM Intelligence 4Market Research LLP is a global business intelligence and consulting firm headquartered in
Hyderabad, India. DataM delivers actionable insights across 15+ industry verticals, offering syndicated reports, customized consulting, and competitive intelligence solutions. The firm's oncology market coverage spans hematologic malignancies, solid tumors, and cell & gene therapies, providing deep-dive data on clinical pipelines, regulatory landscapes, pricing, and market access strategies.
To find out more, visit https://www.datamintelligence.com/ or follow us on Twitter, LinkedIn and Facebook.
Contact:
Sai Kiran
DataM Intelligence 4market Research LLP
Ground floor, DSL Abacus IT Park, Industrial Development Area
Uppal, Hyderabad, Telangana 500039
USA: +1 877-441-4866
Email: [email protected]
Logo: https://mma.prnewswire.com/media/1858619/3573087/DataM_Intelligence_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/next-generation-multiple-myeloma-therapies-market-to-reach-usd-37-07-billion-by-2033--driven-by-accelerated-immunotherapy-approvals-and-precision-medicine-advances--datam-intelligence-302603937.html
Ufficio Stampa
PR Newswire (Leggi tutti i comunicati)
209 - 215 Blackfriars Road
LONDON United Kingdom
